The US FDA has requested manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine drugs from the market immediately.
A novel tetravalent dengue vaccine candidate developed by Takeda is found demonstrating similar degrees of protection in individuals who had and had not been previously infected with dengue.
Entacapone, the commonly used medication for Parkinson’s disease is not associated with increased risk of prostate cancer, said USFDA, confirming the safety of the drug in a recent announcement. In March 2010, the FDA warned the public about a possible risk of prostate cancer with the entacapone component of the product Stalevo, based on the […]
The European Medicines Agency (EMA) has recommended that the multiple sclerosis medicine fingolimod (Gilenya) must not be used in pregnant women and in women able to have children who are not using effective contraception. If a woman becomes pregnant while using fingolimod, the medicine must be stopped, and the pregnancy will have to be closely […]
Two drugs have emerged potential future treatments against Ebola virus demonstrating a cure rate of up to 90% in an ongoing clinical trial in the Democratic Republic of the Congo (DRC). The first-ever multi-drug randomized control trial, initiated by the WHO evaluated the safety and efficacy of four investigational agents – ZMapp, remdesivir, mAb114 and […]
The Union government has mooted a proposal to make it mandatory for all generic medicine manufacturers to print the generic names of drugs on the labels larger than the brand or trade names.
On a trip to Benaras, a 44-year old male developed a fever with chills. Seven days later, as he returned to Mumbai, he was drowsy and unresponsive, and had convulsions at the airport. He was immediately admitted to Hinduja Healthcare, one of the leading hospitals in Khar, Mumbai.
The European Commission approved solriamfetol to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adults with narcolepsy (with or without cataplexy) or obstructive sleep apnea (OSA).
Merck & Co., has announced that their flagship oncology drug, Keytruda (pembrolizumab), failed to show a survival benefit in triple-negative breast cancer (TNBC) patients in the Phase 3 KEYNOTE-119 study.
